Login to Your Account



Clinic Roundup


Tuesday, October 11, 2011
Insmed Inc., of Monmouth Junction, N.J., said the FDA is continuing its clinical hold on Phase III trials of Arikace (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with pseudomonas lung infections. The company said it has not yet received a response from the agency regarding the hold previously placed on Phase III trials of Arikace in patients with nontuberculous mycobacterial lung disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription